v3.25.2
Notes to the interim condensed consolidated statement of (income) loss - Share of net profit - Equity method (Details) - EUR (€)
€ in Thousands
6 Months Ended 12 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Dec. 31, 2024
Investments accounted for using the equity method      
Research and development costs € (44,890) € (46,822)  
General and administrative expenses (14,713) (7,701)  
Net operating loss (62,940) (52,249)  
Financial income 2,427 9,093  
Financial expenses (115,651) (5,586)  
Net financial income (113,224) 3,507  
Income tax 503 (119)  
Net loss for the period (175,882) (49,029)  
Exchange difference on translation of foreign operations (77) 66  
Items that will be reclassified subsequently to profit or loss (260) (220)  
Total comprehensive loss (176,049) (49,175)  
Share of net loss - Equity method € (220) € (168)  
Hepalys Pharma, Inc      
Investments accounted for using the equity method      
Group's share in % 15.00% 15.00% 15.00%
Share of net loss € (334) € (235)  
Elimination of downstream sales 113 66  
Share of net loss - Equity method (220) (168)  
Hepalys Pharma, Inc      
Investments accounted for using the equity method      
Research and development costs 0 (51)  
General and administrative expenses (2,155) (1,475)  
Net operating loss (2,155) (1,526)  
Financial income 2 20  
Financial expenses (5) (3)  
Net financial income (3) 17  
Net loss for the period (2,158) (1,509) € (3,277)
Exchange difference on translation of foreign operations (573) (1,964)  
Items that will be reclassified subsequently to profit or loss (573) (1,964)  
Total comprehensive loss € (2,732) € (3,473)